Thus, multiple FLT3 inhibitors (midostaurin, lestaurtinib, sunitinib, sorafenib, semaxanib, and tandutinib) have been used to reduce the impact of FLT3 mutations and improve the overall survival of AML patients [46,47]. This evidence concerns the gene FLT3 and acute myeloid leukemia.